A Phase Ii, Multicenter Study Of Encorafenib/Binimetinib Followed By A Rational Triple-Combination After Progression In Patients With Advanced Braf V600-Mutated Melanoma (Logic2).Reinhard Dummer,Shahneen Kaur Sandhu,Wilson H. Miller,Marcus O. Butler,Christian U. Blank,Eva Muñoz-Couselo,Howard A. Burris,Michael A. Postow,Bartosz Chmielowski,Mark R. Middleton,Carola Berking,Jessica Cecile Hassel,Anja Gesierich,Cornelia Mauch, Joseph Kleha,Ashwin Gollerkeri, Allison Harney,Michael D Pickard,Paolo Antonio AsciertoJOURNAL OF CLINICAL ONCOLOGY（2020）引用 14|浏览42暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
